Kura, Kyowa Groundbreaking AML Trial: Ziftomenib 93% Complete Remission in Blood Cancer

Kura Oncology and Kyowa Kirin reported positive Phase 1a/1b trial results for ziftomenib combined with 7+3 chemotherapy in newly diagnosed AML patients. The KOMET-007 trial showed impressive complete remission rates of 93% in NPM1-mutant and 89% in KMT2A-rearranged AML patients. Notable MRD-negativity rates were achieved: 71% in NPM1-m and 88% in KMT2A-r patients. The treatment demonstrated favorable safety with no additive myelosuppression. High survival rates were observed with 96% of NPM1-m and 88% of KMT2A-r patients remaining alive and on study. Phase 3 studies (KOMET-017-IC and NIC) are planned to start in second half of 2025. The data suggests ziftomenib's potential as a frontline treatment option for AML patients.

https://www.stocktitan.net/news/KURA/kura-oncology-and-kyowa-kirin-report-positive-updated-combination-bkmq9gjb6ro0.html